4-Azetidinyl-1-phenyl-cyclohexane antagonists of CCR2

1. A compound of Formula (I)

wherein:

X is NH 2 , F, H, SH, S(O)CH 3 , SCH 3 , SO 2 CH 3 , or OH;

R 1 is phenyl optionally substituted with one or two substituents, one of which is selected from the group consisting of: OC (1-4) alkyl, SC (1-4) alkyl, SOC (1-4) alkyl, SO 2 C (1-4) alkyl, —OSO 2 NH 2 , —SO 2 NHC (1-4) alkyl, —OSO 2 NH 2 , —SO 2 NH 2 , N(C (1-4) alkyl) 2 , NH 2 , NHC (1-4) alkyl, NHSO 2 C (1-4) alkyl, N(SO 2 CH 3 ) 2 , OH, OC (1-4) alkylCO 2 C (1-4) alkyl, OC (1-4) alkylCO 2 H, OCH 2 CH 2 N(C (1-4) alkyl) 2 , F, Cl, CH 2 CN, CN, C (1-4) alkyl, NHCO 2 H, NHCO 2 C (1-4) alkyl, NHCOC (1-4) alkyl, —C≡CH, CONH 2 , NHCONH 2 , NHCONHC (1-4) alkyl, CONHC (1-4) alkyl, CH 2 CONHC (1-4) alkyl, C (1-4) alkylCONH 2 , C (1-4) alkylCO 2 C (1-4) alkyl, C (1-4) alkylCO 2 H, CO 2 H, CH 2 C(NH)NH 2 , CO 2 C (1-4) alkyl, CF 3 , OCHF 2 , CHF 2 , OCF 3 , OCH 2 CF 3 , cycloalkyl, heterocyclyl, phenoxy, phenyl, CH 2 -phenyl, CH 2 heteroaryl, and heteroaryl; and the second substituent, if present, is selected from the group consisting of F, C (2-4) alkyl and OCH 3 , or said phenyl may be substituted on two adjacent carbon atoms to form a fused bicyclic system, selected from the group consisting of benzothiazolyl, benzooxazolyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl, are optionally substituted on any nitrogen atom with C (1-4) alkyl;

R 2 is H, C (1-4) alkyl, NH 2 , NO 2 , NHCH 2 CH 2 OH, N(C (1-4) alkyl) 2 , N(SO 2 CH 3 ) 2 , NHCONHC (1-4) alkyl, CN, F, Cl, Br, CF 3 , cycloalkyl, heterocyclyl, OCF 3 , OCF 2 H, CF 2 H, or OC (1-4) alkyl;

R 3 is F, Cl, CF 3 , or OC (1-4) alkyl; alternatively, R 2 and R 3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, or 2,3-dihydro-benzo[1,4]dioxinyl group;

R 4 is H, OC (1-4) alkyl, or F;

and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

2. A compound of claim 1 wherein:

X is NH 2 , F, H, or OH;

R 1 is phenyl optionally substituted with one or two substituents, one of which is selected from the group consisting of: OC (1-4) alkyl, SC (1-4) alkyl, SOC (1-4) alkyl, SO 2 C (1-4) alkyl, —OSO 2 NH 2 , —SO 2 NHC (1-4) alkyl, —OSO 2 NH 2 , —SO 2 NH 2 , N(C (1-4) alkyl) 2 , NH 2 , NHC (1-4) alkyl, NHSO 2 C (1-4) alkyl, N(SO 2 CH 3 ) 2 , OH, OCH 2 CO 2 C (1-4) alkyl, OCH 2 CO 2 H, OCH 2 CH 2 N(CH 3 ) 2 , F, Cl, CH 2 CN, CN, C (1-4) alkyl, NHCO 2 H, NHCO 2 C (1-4) alkyl, NHCOC (1-4) alkyl, —C≡CH, CONH 2 , NHCONH 2 , NHCONHC (1-4) alkyl, CONHC (1-4) alkyl, CH 2 CONHC (1-4) alkyl, CH 2 CONH 2 , CH 2 CO 2 C (1-4) alkyl, CH 2 CO 2 H, CO 2 H, CH 2 C(NH)NH 2 , CO 2 C (1-4) alkyl, CF 3 , OCHF 2 , CHF 2 , OCF 3 , cyclopentyl, cyclohexyl, morpholinyl, piperazinyl, piperidinyl, phenoxy, CH 2 phenyl, phenyl, CH 2 pyridyl, pyridyl, pyrrolidinyl, CH 2 tetrazolyl, and tetrazolyl; and the second substituent, if present, is selected from the group consisting of F, CH 2 CH 3 and OCH 3 , or said phenyl may be substituted on two adjacent carbon atoms to form a fused bicyclic system, selected from the group consisting of 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl, are optionally substituted on any nitrogen atom with C (1-4) alkyl;

R 2 is H, C (1-4) alkyl, NH 2 , NO 2 , NHCH 2 CH 2 OH, N(C (1-4) alkyl) 2 , N(SO 2 CH 3 ) 2 , NHCONHC (1-4) alkyl, CN, F, Cl, Br, CF 3 , pyridinyl, pyrrolidinyl, OCF 3 , OCF 2 H, CF 2 H, or OC (1-4) alkyl;

R 3 is F, Cl, CF 3 , or OC (1-4) alkyl; alternatively, R 2 and R 3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;

R 4 is H, OCH 3 , or F;

and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

3. A compound of claim 2 wherein:

R 1 is phenyl optionally substituted with one or two substituents, one of which is selected from the group consisting of: OC (1-4) alkyl, SC (1-4) alkyl, SO 2 CH 3 , N(C (1-4) alkyl) 2 , NH 2 , NHSO 2 C (1-4) alkyl, N(SO 2 CH 3 ) 2 , OH, F, Cl, CH 2 CN, CN, C (1-4) alkyl, NHCO 2 C(CH 3 ) 3 , OCH 2 CO 2 C (1-4) alkyl, OCH 2 CO 2 H, OCH 2 CH 2 N(CH 3 ) 2 , —C≡CH, CONH 2 , CO 2 H, CO 2 C (1-4) alkyl, CH 2 CO 2 H, CH 2 CO 2 C (1-4) alkyl, CH 2 C(NH)NH 2 , CH 2 CONH 2 , pyrrolidinyl, CH 2 tetrazolyl, and tetrazolyl; and the second substituent, if present, is selected from the group consisting of F, CH 2 CH 3 and OCH 3 , or said phenyl may be substituted on two adjacent carbon atoms to form a fused bicyclic system, selected from the group consisting of 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl, are optionally substituted on any nitrogen atom with C (1-4) alkyl;

R 2 is H, NH 2 , NO 2 , NHCH 2 CH 2 OH, N(CH 3 ) 2 , N(SO 2 CH 3 ) 2 , NHCONHC (1-4) alkyl, CN, F, Cl, Br, CF 3 , pyridinyl, pyrrolidinyl, or OCH 3 ;

R 3 is F, Cl, CF 3 , or OCH 3 ; alternatively, R 2 and R 3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;

R 4 is H, or F;

and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

4. A compound of claim 3 wherein:

R 1 is phenyl optionally substituted with one substituent selected from the group consisting of: OC (1-4) alkyl, SC (1-4) alkyl, SO 2 CH 3 , N(C (1-4) alkyl) 2 , NH 2 , NHSO 2 C (1-4) alkyl, N(SO 2 CH 3 ) 2 , OH, F, Cl, CH 2 CN, CN, C (1-4) alkyl, NHCO 2 C(CH 3 ) 3 , OCH 2 CO 2 C (1-4) alkyl, OCH 2 CO 2 H, OCH 2 CH 2 N(CH 3 ) 2 , —C≡CH, CONH 2 , CO 2 H, CO 2 C (1-4) alkyl, CH 2 CO 2 H, CH 2 CO 2 C (1-4) alkyl, CH 2 C(NH)NH 2 , CH 2 CONH 2 , pyrrolidinyl, CH 2 tetrazolyl, and tetrazolyl; or said phenyl may be substituted with one OCH 3 group and one F, or said phenyl may be substituted on two adjacent carbon atoms to form a fused bicyclic system, selected from the group consisting of 3H-benzothiazol-2-onyl, 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, 1-methyl-1H-benzoimidazolyl, benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, wherein said 3H-benzooxazol-2-onyl, 1,3-dihydro-benzoimidazol-2-onyl, and 1-methyl-1H-benzoimidazolyl, are optionally substituted on any nitrogen atom with C (1-4) alkyl; and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

5. A compound of claim 4 wherein:

R 1 is phenyl,

wherein said phenyl is optionally substituted with one substituent selected from the group consisting of: OCH 3 , SCH 3 , SO 2 CH 3 , N(CH 3 ) 2 , NH 2 , NHSO 2 CH 3 , N(SO 2 CH 3 ) 2 , OH, F, Cl, CH 2 CN, CN, CH 3 , NHCO 2 C(CH 3 ) 3 , OCH 2 CO 2 CH 3 , OCH 2 CO 2 H, OCH 2 CH 2 N(CH 3 ) 2 , —C≡CH, CH 2 CH 3 , CONH 2 , CO 2 H, CO 2 CH 3 , CO 2 CH 2 CH 3 , CH 2 CO 2 H, CH 2 CO 2 CH 2 CH 3 , CH 2 C(NH)NH 2 , CH 2 CONH 2 , pyrrolidinyl, CH 2 tetrazolyl and tetrazolyl; or said phenyl may be substituted with one OCH 3 group and one F;

R 2 is H, F, Br, CF 3 , NO 2 , NH 2 , NHCH 2 CH 2 OH, N(CH 3 ) 2 , N(SO 2 CH 3 ) 2 , NHCONHC (1-4) alkyl, pyrrolidinyl, pyridinyl, OCH 3 ;

R 3 is CF 3 ;

R 4 is H;

and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

6. A compound selected from the group consisting of:

and a hydrate, tautomer or pharmaceutically acceptable salt thereof.

7. A compound of claim 6 selected from the group consisting of:

and a hydrate, tautomer or -pharmaceutically acceptable salt thereof.

8. A compound of claim 7 , which is

and a hydrate, tautomer or-pharmaceutically acceptable-salt thereof.

9. A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

10. A process for making a pharmaceutical composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

11. A process for the preparation of a compound of Formula (I) of claim 1 , comprising reacting a compound of Formula (V)

with a compound of Formula (VI)

in the presence of a reducing agent to provide the compound of Formula (I).

12. A process for the preparation of a compound of Formula (I) of claim 1 , comprising reacting a compound of Formula (XIII)

where R a is OH or Cl, with

in the presence of HOBt/EDCI or Et 3 N to provide the compound of Formula (I).

13. A method of treating a disorder selected from the group consisting of type II diabetes, and obesity comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 7 .